Clinical Strategy of Diagnosing and Following Patients with Nonalcoholic Fatty Liver Disease Based on Invasive and Noninvasive Methods

Overview

Journal J Gastroenterol

Specialty Gastroenterology

Date 2017 Nov 28

PMID 29177681

Citations 27

Authors

Masato Yoneda

Kento Imajo

Hirokazu Takahashi

Yuji Ogawa

Yuichiro Eguchi

Yoshio Sumida

Masashi Yoneda

Miwa Kawanaka

Satoru Saito

Katsutoshi Tokushige

Atsushi Nakajima

Affiliations

Soon will be listed here.

Abstract

Nonalcoholic fatty liver disease (NAFLD) is an important cause of chronic liver injury in many countries. The incidence of NAFLD is rising rapidly in both adults and children, because of the currently ongoing epidemics of obesity and type 2 diabetes. Notably, histological liver fibrosis is recognized as the main predictive factor for the overall long-term outcome of NAFLD, including cardiovascular disease and liver-related mortality. Thus, staging of liver fibrosis is essential in determining the prognosis and optimal treatment for patients with NAFLD and in guiding surveillance for the development of hepatocellular carcinoma (HCC). Whereas liver biopsy remains the gold standard for staging liver fibrosis, it is impossible to enforce liver biopsy in all patients with NAFLD. Noninvasive biological markers, scoring systems and noninvasive modalities are increasingly being developed and investigated to evaluate fibrosis stage of NAFLD patients. This review will highlight recent studies on the diagnosis and staging of NAFLD based on invasive (liver biopsy) or noninvasive (biomarker, scoring systems, US-based elastography and MR elastography) methods.

Citing Articles

Metabolic, behavioral health, and disordered eating comorbidities associated with obesity in pediatric patients: An Obesity Medical Association (OMA) Clinical Practice Statement 2022.

Cuda S, Kharofa R, Williams D, OHara V, Conroy R, Karjoo S Obes Pillars. 2023; 3:100031.

PMID: 37990723 PMC: 10662000. DOI: 10.1016/j.obpill.2022.100031.

A 3-step approach to predict advanced fibrosis in nonalcoholic fatty liver disease: impact on diagnosis, patient burden, and medical costs.

Kobayashi T, Ogawa Y, Shinoda S, Iwaki M, Nogami A, Honda Y Sci Rep. 2022; 12(1):18174.

PMID: 36307441 PMC: 9616882. DOI: 10.1038/s41598-022-22767-z.

Is Hepatocellular Carcinoma in Fatty Liver Different to Non-Fatty Liver?.

Nguyen X, Zhang J, Chin K, Bloom S, Nicoll A Nutrients. 2022; 14(18).

PMID: 36145251 PMC: 9504716. DOI: 10.3390/nu14183875.

MAFLD/NAFLD Biopsy-Free Scoring Systems for Hepatic Steatosis, NASH, and Fibrosis Diagnosis.

Segura-Azuara N, Varela-Chinchilla C, Trinidad-Calderon P Front Med (Lausanne). 2022; 8:774079.

PMID: 35096868 PMC: 8792949. DOI: 10.3389/fmed.2021.774079.

Comparison of Non-Invasive Clinical Algorithms for Liver Fibrosis in Patients With Chronic Hepatitis B to Reduce the Need for Liver Biopsy: Application of Enhanced Liver Fibrosis and Mac-2 Binding Protein Glycosylation Isomer.

Hur M, Park M, Moon H, Choe W, Lee C Ann Lab Med. 2021; 42(2):249-257.

PMID: 34635616 PMC: 8548241. DOI: 10.3343/alm.2022.42.2.249.

References

Noureddin M, Yates K, Vaughn I, Neuschwander-Tetri B, Sanyal A, McCullough A . Clinical and histological determinants of nonalcoholic steatohepatitis and advanced fibrosis in elderly patients. Hepatology. 2013; 58(5):1644-54. PMC: 3760979. DOI: 10.1002/hep.26465. View

Bannas P, Kramer H, Hernando D, Agni R, Cunningham A, Mandal R . Quantitative magnetic resonance imaging of hepatic steatosis: Validation in ex vivo human livers. Hepatology. 2015; 62(5):1444-55. PMC: 4652324. DOI: 10.1002/hep.28012. View

Ratziu V, Bellentani S, Cortez-Pinto H, Day C, Marchesini G . A position statement on NAFLD/NASH based on the EASL 2009 special conference. J Hepatol. 2010; 53(2):372-84. DOI: 10.1016/j.jhep.2010.04.008. View

Ekstedt M, Hagstrom H, Nasr P, Fredrikson M, Stal P, Kechagias S . Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up. Hepatology. 2014; 61(5):1547-54. DOI: 10.1002/hep.27368. View

Eguchi Y, Hyogo H, Ono M, Mizuta T, Ono N, Fujimoto K . Prevalence and associated metabolic factors of nonalcoholic fatty liver disease in the general population from 2009 to 2010 in Japan: a multicenter large retrospective study. J Gastroenterol. 2012; 47(5):586-95. DOI: 10.1007/s00535-012-0533-z. View

Yoneda M, Mawatari H, Fujita K, Endo H, Iida H, Nozaki Y . Noninvasive assessment of liver fibrosis by measurement of stiffness in patients with nonalcoholic fatty liver disease (NAFLD). Dig Liver Dis. 2007; 40(5):371-8. DOI: 10.1016/j.dld.2007.10.019. View

Nielsen M, Veidal S, Karsdal M, Orsnes-Leeming D, Vainer B, Gardner S . Plasma Pro-C3 (N-terminal type III collagen propeptide) predicts fibrosis progression in patients with chronic hepatitis C. Liver Int. 2014; 35(2):429-37. DOI: 10.1111/liv.12700. View

Kim D, Kim W, Talwalkar J, Kim H, Ehman R . Advanced fibrosis in nonalcoholic fatty liver disease: noninvasive assessment with MR elastography. Radiology. 2013; 268(2):411-9. PMC: 3721049. DOI: 10.1148/radiol.13121193. View

Liu Y, Reeves H, Burt A, Tiniakos D, McPherson S, Leathart J . TM6SF2 rs58542926 influences hepatic fibrosis progression in patients with non-alcoholic fatty liver disease. Nat Commun. 2014; 5:4309. PMC: 4279183. DOI: 10.1038/ncomms5309. View

10.

Osaki A, Kubota T, Suda T, Igarashi M, Nagasaki K, Tsuchiya A . Shear wave velocity is a useful marker for managing nonalcoholic steatohepatitis. World J Gastroenterol. 2010; 16(23):2918-25. PMC: 2887589. DOI: 10.3748/wjg.v16.i23.2918. View

11.

Yin M, Glaser K, Talwalkar J, Chen J, Manduca A, Ehman R . Hepatic MR Elastography: Clinical Performance in a Series of 1377 Consecutive Examinations. Radiology. 2015; 278(1):114-24. PMC: 4688072. DOI: 10.1148/radiol.2015142141. View

12.

Williams A, Hoofnagle J . Ratio of serum aspartate to alanine aminotransferase in chronic hepatitis. Relationship to cirrhosis. Gastroenterology. 1988; 95(3):734-9. DOI: 10.1016/s0016-5085(88)80022-2. View

13.

Schwimmer J, Behling C, Angeles J, Paiz M, Durelle J, Africa J . Magnetic resonance elastography measured shear stiffness as a biomarker of fibrosis in pediatric nonalcoholic fatty liver disease. Hepatology. 2017; 66(5):1474-1485. PMC: 5650504. DOI: 10.1002/hep.29241. View

14.

Ludwig J, Viggiano T, MCGILL D, Oh B . Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin Proc. 1980; 55(7):434-8. View

15.

Fraquelli M, Rigamonti C, Casazza G, Conte D, Donato M, Ronchi G . Reproducibility of transient elastography in the evaluation of liver fibrosis in patients with chronic liver disease. Gut. 2007; 56(7):968-73. PMC: 1994385. DOI: 10.1136/gut.2006.111302. View

16.

Lazo M, Clark J . The epidemiology of nonalcoholic fatty liver disease: a global perspective. Semin Liver Dis. 2008; 28(4):339-50. DOI: 10.1055/s-0028-1091978. View

17.

Chen J, Yin M, Talwalkar J, Oudry J, Glaser K, Smyrk T . Diagnostic Performance of MR Elastography and Vibration-controlled Transient Elastography in the Detection of Hepatic Fibrosis in Patients with Severe to Morbid Obesity. Radiology. 2016; 283(2):418-428. PMC: 5395333. DOI: 10.1148/radiol.2016160685. View

18.

Sumida Y, Yoneda M, Hyogo H, Yamaguchi K, Ono M, Fujii H . A simple clinical scoring system using ferritin, fasting insulin, and type IV collagen 7S for predicting steatohepatitis in nonalcoholic fatty liver disease. J Gastroenterol. 2010; 46(2):257-68. DOI: 10.1007/s00535-010-0305-6. View

19.

Younossi Z, Koenig A, Abdelatif D, Fazel Y, Henry L, Wymer M . Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2015; 64(1):73-84. DOI: 10.1002/hep.28431. View

20.

Kleiner D, Brunt E, Van Natta M, Behling C, Contos M, Cummings O . Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology. 2005; 41(6):1313-21. DOI: 10.1002/hep.20701. View